Clinical Trial Update: Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating semaglutide for obesity and heart failure has completed, with results posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 3 | Status: COMPLETED | Results posted: 2024-06-11